Tivic Health Systems Inc. has released its financial results for the second quarter and the first half of 2025. The company reported a net revenue of $86,000 for the three months ended June 30, 2025, a decrease from $140,000 in the same period in 2024. For the first half of 2025, net revenue was $156,000, down from $474,000 in the first half of 2024. This decline was primarily due to lower unit sales of ClearUP™, attributed to decreased advertising expenses as the company redirected resources to its TLR5 program for developing Entolimod™ for Acute Radiation Syndrome $(ARS.UK)$. Gross profit for the quarter was reported at $54,000, compared to $30,000 in the second quarter of 2024, with a gross margin of 67% for the first half of 2025, up from 42% in 2024. The operating expenses for the three and six months ended June 30, 2025, increased to $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024, due to the introduction of biopharma programs in February 2025. The net loss for the second quarter of 2025 was $1.9 million, compared to a net loss of $1.3 million in the same period of the previous year. For the first half of 2025, the net loss was $3.4 million, up from $2.7 million in the first half of 2024. Tivic Health also highlighted its strategic transformation with an expansion into biopharmaceuticals, underlining its unique approach to treating diseases by addressing both biochemical and bioelectronic systems. As of June 30, 2025, the company reported cash and cash equivalents of $1.2 million, down from $2.0 million at the end of 2024. Following the quarter's end, Tivic raised $0.9 million through its equity line of credit and the sale of Series B Preferred Stock, with approximately $7.0 million remaining available as a committed investment through a preferred equity purchase agreement. The company believes this funding is sufficient to advance toward manufacturing validation for Entolimod.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814639332) on August 14, 2025, and is solely responsible for the information contained therein.
